TSPO Biomarker Shows Promise for Early Alzheimer's Detection Years Before Symptom Onset
核心洞察
TSPO (搜索), a brain inflammation biomarker, can detect Alzheimer's disease years before memory loss symptoms appear, according to a new study published in Acta Neuropathologica.
Researchers detected elevated TSPO (搜索) levels in mouse models as early as six weeks of age, equivalent to 18-20 years in humans, with highest concentrations in microglia clustered around amyloid plaques.
The findings were validated using brain tissue from Colombian families carrying the "paisa" mutation, who typically develop symptoms in their 30s-40s and die in their 50s.
TSPO (搜索) (translocator protein 18 kDa), a key biomarker of brain inflammation, could revolutionize early detection of Alzheimer's disease by identifying the condition years before memory loss and other symptoms manifest, according to groundbreaking research published in Acta Neuropathologica.
The study, led by Tomás R. Guilarte, dean of Florida International University's Robert Stempel College of Public Health & Social Work, represents the first comprehensive examination of how early this biomarker increases and where it begins rising in the brain. "If we can use this information to help delay Alzheimer's progression by even five years, it can drastically improve patients' lives and reduce disease prevalence," Guilarte said.
Novel Detection Timeline Established
Using advanced imaging software, researchers tracked TSPO (搜索) levels in genetically engineered mouse models of familial Alzheimer's disease and validated their findings with human brain tissue from members of the world's largest group of individuals with early-onset familial Alzheimer's in Antioquia, Colombia.
The mouse model revealed elevated TSPO (搜索) levels in the subiculum—a critical part of the hippocampus—as early as six weeks of age, roughly equivalent to 18-20 years in humans. Microglia, the brain's primary immune cells, particularly those clustered around amyloid plaques, exhibited the highest TSPO concentrations.
Gender Disparities Mirror Clinical Reality
The research uncovered significant gender differences, with female mice displaying higher TSPO (搜索) levels than males. This finding aligns with real-world epidemiological data showing that two-thirds of Alzheimer's patients are women, suggesting the biomarker may help explain sex-based disease susceptibility patterns.
Colombian Cohort Validates Findings
The study's human validation component utilized brain tissue samples from Colombian families carrying the "paisa" mutation, first identified by the late Dr. Francisco Lopera, a co-author who dedicated his career to Alzheimer's prevention research. Carriers of this mutation typically develop symptoms in their 30s to 40s and die in their 50s.
Brain tissue analysis from these patients revealed identical patterns to the mouse models. Even in late-stage Alzheimer's disease, TSPO (搜索) remained elevated in microglia near amyloid plaques, confirming the biomarker's persistence throughout disease progression.
Therapeutic Implications Under Investigation
The findings raise critical questions about TSPO (搜索)'s functional role—whether it contributes to neuronal damage or serves a protective function—and whether therapeutic interventions targeting this protein could halt disease progression. The research team is currently investigating these possibilities using a specially developed Alzheimer's mouse model lacking TSPO.
"The more we understand these processes, the closer we get to tailoring treatments that can truly help—before it's too late," said Daniel Martínez Pérez, the study's first author and Ph.D. candidate in Guilarte's laboratory.
Expanding Research Scope
The investigators are extending their research to include sporadic, late-onset Alzheimer's cases, which account for over 90% of all diagnoses. This expansion could potentially broaden the biomarker's clinical applicability beyond the rare familial forms of the disease.
Guilarte, who has studied TSPO (搜索) for more than three decades, previously helped establish the protein as a reliable imaging biomarker for diagnosing neuroinflammation across various neurodegenerative, neurological, and psychiatric disorders. His expertise positions this research at the forefront of early Alzheimer's detection methodology.